Treace Medical Presents 5-Year ALIGN3D Data Showing 0.8% Recurrence Rate Alongside MTA3D And SPRINT Clinical Results At AOFAS 2026

Treace Medical Concepts, Inc. (NASDAQ: TMCI) presented results from three clinical studies at the AOFAS Annual Meeting, including the 5-year ALIGN3D data showing a 0.8% recurrence rate for their Lapiplasty procedure. The presentations also covered findings from the MTA3D Adductoplasty and SPRINT SpeedPlate studies, highlighting the company's advancements in surgical treatments for bunions and foot & ankle conditions.